10.12
-0.16 (-1.56%)
| Previous Close | 10.28 |
| Open | 10.04 |
| Volume | 210 |
| Avg. Volume (3M) | 345 |
| Market Cap | 330,201,440 |
| Price / Earnings (TTM) | 7.53 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -79.94% |
| Operating Margin (TTM) | -2,318.99% |
| Diluted EPS (TTM) | 1.34 |
| Quarterly Revenue Growth (YOY) | 5,556.00% |
| Total Debt/Equity (MRQ) | 2.33% |
| Current Ratio (MRQ) | 9.00 |
| Operating Cash Flow (TTM) | -130.36 M |
| Levered Free Cash Flow (TTM) | -35.38 M |
| Return on Assets (TTM) | -15.49% |
| Return on Equity (TTM) | -23.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (GB) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | PROTHENA CORPORATION PLC PROTHE | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 1.13 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| PROTHENA CORPORATION PLC PROTHE | 330 M | - | 7.53 | - |
| PHARMA MAR SA PHARMA MAR ORD SH | 16 B | 1.08% | 14.69 | - |
| ARROWHEAD PHARMACEUTICALS INC A | 4 B | - | - | - |
| GENUS PLC ORD 10P | 2 B | 0.01% | 81.55 | 3.61 |
| BASILEA PHARMACEUTICA AG BASILE | 511 M | - | - | 6.18 |
| AVACTA GROUP PLC ORD 10P | 353 M | - | - | 2.35 |
|
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 18.99% |
| % Held by Institutions | 74.35% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |